Functional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl)ation of TRF1 and telomere elongation - PubMed (original) (raw)

Functional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl)ation of TRF1 and telomere elongation

Hiroyuki Seimiya et al. Mol Cell Biol. 2004 Mar.

Abstract

In human cells, telomere elongation by telomerase is repressed in cis by the telomeric protein TRF1. Tankyrase 1 binds TRF1 via its ankyrin domain and poly(ADP-ribosyl)ates it. Overexpression of tankyrase 1 in telomerase-positive cells releases TRF1 from telomeres, resulting in telomere elongation. The tankyrase 1 ankyrin domain is classified into five conserved subdomains, ARCs (ankyrin repeat clusters) I to V. Here, we investigated the biological significance of the ARCs. First, each ARC worked as an independent binding site for TRF1. Second, ARCs II to V recognized the N-terminal acidic domain of TRF1 whereas ARC I bound a discrete site between the homodimerization and the Myb-like domains of TRF1. Inactivation of TRF1 binding in the C-terminal ARC, ARC V, either by deletion or point mutation, significantly reduced the ability of tankyrase 1 to poly(ADP-ribosyl)ate TRF1, release TRF1 from telomeres, and elongate telomeres. In contrast, other ARCs, ARC II and/or IV, inactivated by point mutations still retained the biological function of tankyrase 1. On the other hand, ARC V per se was not sufficient for telomere elongation, suggesting a structural role for multiple ARCs. This work provides evidence that specific ARC-TRF1 interactions play roles in the essential catalytic function of tankyrase 1.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Schematic view of tankyrase 1 constructs used in the experiments. (A) LexA-ARC constructs used as described for Fig. 2, 3, and 5. (B and C) FN-tankyrase 1 constructs used as described for Fig. 2D, 4, and 6 to 8. These constructs contain a FLAG epitope tag and an NLS at the N terminus (data not shown). The numbers indicate the positions of amino acid residues. HPS, region containing homopolymeric runs of His, Pro, and Ser; ANK, ankyrin domain; SAM, multimerization domain homologous to the sterile alpha motif; PARP, PARP catalytic domain; ARC, ANK repeat cluster. Bridges above two adjacent ANK repeats indicate the presence of a conserved histidine, contributing to interrepeat stabilization.

FIG. 2.

FIG. 2.

Tankyrase 1 ARCs work as independent ligand binding sites. (A) In vitro pull-down assay of LexA-ARCs with GST-tankyrase 1 binding proteins. The indicated GST fusions (bound to beads) were incubated with in vitro-translated LexA-ARCs. The bead-bound LexA fusions were detected by Western blot (WB) analysis (left panel). GST fusions were visualized by Coomassie blue staining (right panel). Molecular mass markers (in kilodaltons) are indicated at the right. (B) Phylogenetic tree of ARCs in tankyrase 1 and 2. Amino acid sequences for ARCs were aligned with ClustalW software (

http://www.ddbj.nig.ac.jp/E-mail/clustalw-e.html

). The tree was created using DendroMaker software (

http://www.cib.nig.ac.jp/dda/timanish/dendromaker/home.html

). (C) Interaction of tankyrase 1 with TAB182 is competitively inhibited by TRF1. In vitro-translated FN-tankyrase 1 and TAB182C were incubated with increasing amounts of GST-TRF1 (0, 0.1, or 1 μg) or GST (5 μg). FN-tankyrase 1 was immunoprecipitated (IP) with anti-FLAG antibody, and bead-bound TAB182C was detected by Western blot analysis. The filter was reprobed with anti-GST antibody. (D) The presence of a single functional ARC is sufficient for the interaction of tankyrase 1 with TRF1. Deletion mutants were prepared by in vitro translation and subjected to a pull-down assay with GST-TRF1. The bead-bound proteins were detected by Western blot analysis (left panel). The results of Coomassie staining of GST-TRF1 are also shown (right panel). Molecular mass markers (in kilodaltons) are indicated at the left of each panel.

FIG. 3.

FIG. 3.

Tankyrase 1 ARCs recognize discrete domains of TRF1. (A) GST-TRF1 constructs used in the experiments. The numbers indicate the positions of amino acid residues. (B) Pull-down assays were performed with in vitro-translated FN-tankyrase 1 and various GST-TRF1 fusions. Bead-bound FN-tankyrase 1 was detected by Western blot (WB) analysis (left panel). GST fusions were visualized by Coomassie blue staining (right panel). Molecular mass markers (in kilodaltons) are indicated to the right of each panel. (C) Specificity of ARCs for TRF1 binding. Pull-down assays were performed with in vitro-translated LexA-ARCs and recombinant GST-TRF1 fusions. (Top panel) The bead-bound LexA-fusions were detected as described for Fig. 2A. (Bottom panel) Deduced ARC binding sites in TRF1. (D) ARCs bind TRF1 in intact cells. LexA-ARCs and Myc-TRF1 or Myc-TRF1(2-210) were transiently expressed in HeLa I.2.11 cells, and the lysates were immunoprecipitated (IP) as indicated. The bead-bound LexA fusions were detected by Western blot analysis.

FIG. 4.

FIG. 4.

Tankyrase 1 deletion mutants retaining ARC V still show TRF1-releasing activity. (A) Effects of transient overexpression of FN-tankyrase 1 constructs on telomeric localization of TRF1 in HeLa I.2.11 cells. Cells were transfected with vectors as indicated. FN-tankyrase 1 constructs, TRF1, and TRF2 were detected by indirect immunofluorescence staining with anti-FLAG M2 (green), anti-TRF1 5747 (red), and anti-TRF2 4A794 (red) antibodies, respectively. DAPI staining of DNA is shown in blue. (B) Quantitation of the TRF1-releasing activity. Cells displaying overexpression of the FN-tankyrase 1 constructs were classified into three categories (depending on the appearance of TRF1 dots): complete disappearance, partial disappearance (i.e., observed but obviously decayed compared with those in surrounding nontransduced cells), and no effect (i.e., intensity comparable with that of mock- and nontransduced cells). Closed circles indicate the existence of intact ARCs.

FIG. 5.

FIG. 5.

ARC point mutations that disrupt the TRF1 binding. (A) (Top panel) Secondary structure of ANK repeat. Arrows and rectangles indicate the approximate positions of the β-strands and α-helices, respectively. (Middle panel) Alignment of the third ANK repeat (AR) in several ANK family proteins and tankyrase 1 ARCs II, IV, and V. Conserved residues are in boldface type. (Bottom panel) Topological diagram of the secondary-structure elements of typical ARC. Circles indicate the α-helices with helix axes perpendicular to the plane of the figure. The asterisk indicates the conserved proline, which was replaced with leucine in this study. (B) Replacement of the conserved proline with leucine abolished the TRF1 binding of ARCs. In vitro-translated LexA-ARC mutants (mt) were subjected to a pull-down assay with GST-TRF1 or GST (as described for Fig. 2A). The bead-bound LexA fusions were detected by Western blot analysis (WB) (top panels). The results of Coomassie blue staining of GST-TRF1 are also shown (bottom panels).

FIG. 6.

FIG. 6.

Inactivation of ARC V abolishes the TRF1-releasing activity of tankyrase 1. (A) Effects of transient overexpression of the point mutant FN-tankyrase 1 on telomeric localization of TRF1 in HeLa I.2.11 cells. Cells were transfected with vectors as indicated. FN-tankyrase 1 constructs (green), TRF1 (red), and DNA (blue) were detected as described for Fig. 4A. (B) Quantitation of the TRF1-releasing activity. Cells displaying overexpression of the FN-tankyrase 1 constructs were classified into three categories as described for Fig. 4B. Closed and open circles indicate wild-type and Pro→Leu mutant (mt) ARCs, respectively.

FIG. 7.

FIG. 7.

Differential requirements of multiple ARCs for telomere elongation by tankyrase 1. (A) Effects of overexpression of FN-tankyrase 1 constructs on telomere length in HTC75 cells. TRF at the indicated PD were detected by Southern blot analysis. The results of two representative experiments are shown. M, mock; WT-Tank, wild-type FN-tankyrase 1; mt, mutant. (B) Graphic representations of telomere length change. The plots represent the mean TRF values derived the results presented in panel A. (C) Western blot analysis of whole-cell or nuclear extracts (20 μg of proteins per lane). Blots were probed with antibodies as indicated. For detection of self-poly(ADP-ribosyl)ation, lysates were immunoprecipitated (IP) with anti-FLAG antibody and the pellets were subjected to Western blot analysis with anti-poly(ADP-ribose). MW, molecular mass.

FIG. 8.

FIG. 8.

Crucial requirement of ARC V for poly(ADP-ribosyl)ation of TRF1 in vitro. (A) Poly(ADP-ribosyl)ation of TRF1 by FN-tankyrase 1 constructs in vitro. Whole-cell extracts were immunoprecipitated with anti-FLAG M2 agarose. The beads were washed and incubated with 4 μg of GST-TRF1 and 1.3 μM [32P]NAD+. +3AB, 1 mM 3-aminobenzamide (3AB) was added prior to addition of GST-TRF1. Reactions were terminated by adding TCA and fractionated by SDS-PAGE. Poly(ADP-ribosyl)ated GST-TRF1 was detected by autoradiography (upper panels). Small aliquots of the beads were subjected to Western blot analysis (WB) with anti-tankyrase antibody (lower panels). mt, mutant. (B) Quantitation of PARP activity in each construct. Radioactivity in the area corresponding to the size of GST-TRF1 was quantitated with a Fuji BAS imaging analyzer. Bars indicate the averages of values obtained in four to five independent experiments. Asterisks indicate statistically significant differences (evaluated using an unpaired t test and FN-tank-ΔANK).

Similar articles

Cited by

References

    1. Bianchi, A., S. Smith, L. Chong, P. Elias, and T. de Lange. 1997. TRF1 is a dimer and bends telomeric DNA. EMBO J. 16:1785-1794. - PMC - PubMed
    1. Bianchi, A., R. M. Stansel, L. Fairall, J. D. Griffith, D. Rhodes, and T. de Lange. 1999. TRF1 binds a bipartite telomeric site with extreme spatial flexibility. EMBO J. 18:5735-5744. - PMC - PubMed
    1. Blackburn, E. H. 2001. Switching and signaling at the telomere. Cell 106:661-673. - PubMed
    1. Blasco, M. A., H.-W. Lee, M. P. Hande, E. Samper, P. M. Lansdorp, R. A. DePinho, and C. W. Greider. 1997. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91:25-34. - PubMed
    1. Bodnar, A. G., M. Ouellette, M. Frolkis, S. E. Holt, C.-P. Chiu, G. B. Morin, C. B. Harley, J. W. Shay, S. Lichtsteiner, and W. E. Wright. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-352. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources